Top

Published in:

Open Access 01-02-2021 | Acute Lymphoblastic Leukemia | Letter to the Editor

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia

Authors: Ramona Wullenkord, Christian Reicherts, Jan-Henrik Mikesch, Julia Marx, Klaus Wethmar, Jörn Albring, Simon Call, Georg Lenz, Matthias Stelljes

Published in: Annals of Hematology | Issue 2/2021

Excerpt

Dear Editor, …

Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 119(1):34–43. https://doi.org/10.1182/blood-2011-04-347872CrossRefPubMedPubMedCentral

Gokbuget N (2016) Treatment of older patients with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016(1):573–579. https://doi.org/10.1182/asheducation-2016.1.573CrossRefPubMedPubMedCentral

Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S (2018) New approaches to the management of adult acute lymphoblastic leukemia. J Clin Oncol JCO2017773648. https://doi.org/10.1200/JCO.2017.77.3648

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gokbuget N, O’Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740–753. https://doi.org/10.1056/NEJMoa1509277CrossRefPubMedPubMedCentral

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gokbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM (2018) Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer 124(8):1722–1732. https://doi.org/10.1002/cncr.31249CrossRefPubMed

Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836–847. https://doi.org/10.1056/NEJMoa1609783CrossRefPubMedPubMedCentral

Kantarjian HM, Stein AS, Bargou RC, Grande Garcia C, Larson RA, Stelljes M, Gokbuget N, Zugmaier G, Benjamin JE, Zhang A, Jia C, Topp MS (2016) Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer 122(14):2178–2185. https://doi.org/10.1002/cncr.30031CrossRefPubMed

Park JH, Geyer MB, Brentjens RJ (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127(26):3312–3320. https://doi.org/10.1182/blood-2016-02-629063CrossRefPubMedPubMedCentral

Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459. https://doi.org/10.1056/NEJMoa1709919CrossRefPubMedPubMedCentral

10.

Sawalha Y, Advani AS (2018) Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. Int J Hematol Oncol 7(1):IJH02. https://doi.org/10.2217/ijh-2017-0023CrossRefPubMedPubMedCentral

11.

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL (2020) Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol JCO1902104. https://doi.org/10.1200/JCO.19.02104

Title: Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia
Authors: Ramona Wullenkord
Christian Reicherts
Jan-Henrik Mikesch
Julia Marx
Klaus Wethmar
Jörn Albring
Simon Call
Georg Lenz
Matthias Stelljes
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Acute Lymphoblastic Leukemia
CAR T-Cell Therapy
Blinatumomab
Inotuzumab Ozogamicin
Cytostatic Therapy
Published in: Annals of Hematology / Issue 2/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04227-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2021

Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis

Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Krüppel-like factor 1 (KLF1) gene single nucleotide polymorphisms in sickle cell disease and its association with disease-related morbidities

Correction to: Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis

Primary pulmonary diffuse large B cell lymphoma presenting as bulky bilateral lung tumors

COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page